Fusion glycoprotein F0

Fusion glycoprotein F0

Fusion glycoprotein F0 Informations sur la molécule

Molecule Name
Respiratory syncytial virus F protein
Alias de la molécule
Fusion glycoprotein F0
Drug Development Progress
Nombre de médicaments cliniques5
Nombre de médicaments commercialisés3
Phase de R&D la plus avancéeApproved
Alias de la cible
Protein F,F,Fusion glycoprotein F0
Contexte de la molécule
The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology Inc
Respiratory Syncytial Virus Infections
Details
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences Inc
Respiratory Syncytial Virus Infections
Details
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd
Respiratory Syncytial Virus Infections
Details
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
Details
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research Institute
Respiratory Syncytial Virus Infections
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31
Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19
Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
Details
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01
Respiratory Syncytial Virus Infections
Details